Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company (NASDAQ: IMNP) ("Immune" or the...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company") announced today that its oncology subsidiary, Cytovia Inc. ("Cytovia") has reached...
Immune Pharmaceuticals (NASDAQ:IMNP) ("Immune"), a clinical stage biopharmaceutical company, announced today that patient enrollment in a Phase I/II...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company") announced today that on June 15, 2017, the Company received written notice from the Nasdaq ...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ('Immune') announced today that it has signed an agreement with Meda, a Mylan NV company ('Mylan') to...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company") announced today that on May 24, 2017, the Company received written notice from Nasdaq that ...
Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company") today announced that it has entered into definitive agreements with several...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company"), a biopharmaceutical company focused on the development of targeted...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced that on April 18, 2017 the Company has received written notice from the Listing...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or "Immune Pharma") announced today that it has entered into a letter of intent with Pint Pharma ...
Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company"), today announced a reverse stock split of its shares of common stock at a...
Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company"), announced today that following a hearing on March 9, 2017, where the Company...
Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company") today announced that it has broadened enrollment eligibility criteria based on ...
Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that...
Immune Pharmaceuticals Inc. (Nasdaq: IMNP), announced today it has appointed Ranch C. Kimball, a highly regarded executive in healthcare, government, ...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Immune Pharmaceuticals (NASDAQ: IMNP) ("Immune"), a clinical stage biopharmaceutical company, announced today that it will hold a Satellite Symposium ...
Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune"), announced today that it intends to request a hearing before the Nasdaq Listing Qualifications...
Immune Pharmaceuticals (NASDAQ: IMNP) (Immune) announced today that it will hold an Immuno-Oncology R&D Update for investors on December 8, 2016 in...
Immune Pharmaceuticals (NASDAQ:IMNP) (Immune) announced today that it has secured up to $11 million in new financing from a single family office that ...
Immune Pharmaceuticals (NASDAQ:IMNP) (Immune) announced today that it has received guidance from the United States Food and Drug Administration (FDA) ...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a consulting agreement with Joseph V. Pergolizzi Jr.,...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the...
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") announced financial results for the second quarter and six months ended June...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.